Degradation by design

76Bio aims to develop transformational therapies for patients with life-threatening disease by pioneering the next generation of targeted protein degraders.

76Bio

Meet our Team

Management

Sean Algeo
Sean Algeo, CPA
Controller & Treasurer
Marius Pop
Marius Pop, PhD
VP Biology
Alexandra Snyder
Alexandra Snyder
VP Clinical Translation
Nichole van de Leuv
Nicole van de Leuv
VP Legal
Christopher Wilfong
Christopher Wilfong
President & CEO

Scientific Advisors, Directors and Co-founders

Arie Belldegrun
Arie Belldegrun, MD
Bellco Capital
Joshua Kazam
Joshua Kazam
Two River
Angela Koehler, PhD
Angela Koehler, PhD
MIT
Charles Lin, PhD
Charles Lin, PhD
Kronos Bio
David Tanen
David Tanen
Two River
Owen Witte
Owen Witte, MD
UCLA
K. Dane Wittrup, PhD
K. Dane Wittrup, PhD
MIT